Join
Live feed
·
PRReleasevia Quantisnow
Recursion Pharmaceuticals Inc. logo

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

ByQuantisnow·Wall Street's wire, on your screen.
RXRX· Recursion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXRX (Recursion Pharmaceuticals Inc.) and more on Quantisnow.